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Objectives: The aim of the study was to assess the prevalence and risk factors 
of diabetic retinopathy (DR) in type 2 diabetes mellitus patients (T2DM) of North 
India. MethOds: It is a prospective observational study conducted at endocrinology 
clinic of a public tertiary care hospital in north India. Patients of either gender with 
greater than 18 years of age and having the diagnosis of T2DM were recruited in the 
study. Each and every patient had undergone fundus photography examination and 
data was taken from patient’s medical records. Binary logistic regression was done 
to assess the risk factors. Results: A total of 2,006 T2DM subjects were recruited 
in the study with the mean age of 53.8 ± 7.88 years, and mean duration of diabetes 
10.5 ± 7.3 years, among them 505 subjects were found to have DR accounting for 
25.2% (95% confidence interval (CI), 23.2-27.07) prevalence. Binary logistic regression 
analysis has shown that female gender (Odds ratio (OR), 1.42, CI 1.1-1.9, p = 0.01), 
smoking (OR, 2.1, CI 1.3-3.3, p = 0.001) and duration of diabetes OR, 1.07, CI 1.05-1.09, 
p < 0.001) were significantly associated with increased risk of DR. cOnclusiOns: 
This study showed higher prevalence of DR in Indian population thus suggesting a 
need of regular eye examination.
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Objectives: In Germany, regional data on diabetes prevalence are scarce. Robust 
regional prevalence estimates are required for allocating limited health care 
resources appropriately. The aim of this study was to determine the regional diabe-
tes prevalence in Germany for 2011 and 2022. MethOds: A large database contain-
ing 80 percent of all prescriptions redeemed in German pharmacies and accounted 
by the statutory health insurance (SHI) was analyzed. By defining a prescription 
filter for anti-diabetic agents, the numbers of drug treated diabetic patients in dif-
ferent age and sex groups were estimated for all 16 federal states in Germany. A 
multiple linear regression model was used to adjust the values to the whole SHI 
population with the help of an additional database containing exhaustive drug sales 
data. Crude prevalence was calculated using SHI member statistics. By using popu-
lation data of the federal statistical office, age- and sex-standardized prevalences 
for 2011 were estimated and projected to the year 2022. Results: In total, 5809403 
patients were found for 2011, which means a crude prevalence of 8.38% (standard-
ized: 8.18%) for Germany. The highest prevalence was found in the East German 
state Saxony-Anhalt with 12.74% (12.13%), the lowest in the northernmost state 
Schleswig-Holstein with 6.05% (6.07%). Prevalence was higher in men with 8.84% 
(8.68%) than in women with 7.98% (7.71%). In 2022, the standardized total prevalence 
amounts to 9.34% in Germany. cOnclusiOns: This method to estimate diabetes 
prevalence by means of prescription data presents valid results compared to other 
epidemiological studies. A simple, fast and re-usable algorithm allows calculating 
nationwide prevalence estimates on a regional level by secondary use of large data 
sources. Quick analyses and demographic forecasts can support care providers and 
payors to plan health care and expenses more efficiently to match current and 
future regional demand.
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Objectives: Type 2 diabetes (T2D) continues to be a public health concern, affecting 
an estimated 371 million of the world’s population. The objective of this analysis 
is to review epidemiologic and treatment pattern trends among US adults with 
T2D. MethOds: This analysis utilized cross-sectional data from the US National 
Health and Wellness Survey (NHWS) from 2006 (n= 62,834) through 2013 (n= 75,000). 
A stratified random sampling based on gender, age, and race/ethnicity was used to 
ensure representativeness to the adult population, based on the US Census Bureau. 
Descriptive analyses were conducted by each year to determine changes in the over-
all T2D population with respect to demographics, HbA1c levels, complications, treat-
ment, and time-to-insulin or oral/non-insulin injectable medications. Results: 
The overall prevalence of T2D fluctuated slightly from 2006 to 2013, ranging from 
9.2% to 10.2% over time. While the mean age at diagnosis for T2D patients has been 
consistently in the late forties, from 2006 to 2013 the mean age at diagnosis has 
decreased by 1.5 years overall (49.9 to 48.4 years). Though the majority of patients 
are non-Hispanic White, there has been a slow increase in the proportion of patients 
who are African-American or Hispanic (24.5% in 2006 vs 26.6% in 2013). The propor-
tion of patients who are using an oral medication, insulin, or non-insulin injectable 
has steadily increased (80.4% in 2006 to 82.5% in 2013). Mean years from diagnosis 
to using insulin has steadily increased, as well as usage of newer classes of medica-
tions such as GLP-1 (1.9% in 2006 to 4.2% in 2013). Knowledge of HbA1c has increased 
steadily from 2006 to 2013. cOnclusiOns: While some of trends among US adult 
T2D patients have remained steady, since 2006 there has been earlier diagnosis, 
more Non-White patients, increases in treatment, and greater HbA1c awareness.
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Objectives: Rising rates of diabetes in Africa have triggered increased demand 
for affordable medical solutions. This analysis sought to quantify the burden of 
diabetes in Africa, and identify regions where disease burden creates opportunity 
for pharmaceutical and medical device interventions. MethOds: Data from the 
International Diabetes Federation was used to estimate the prevalence of diabetes 
mellitus and the mean national expenditure in 53 African countries. A systematic 
literature search was conducted to capture current disease management proto-
cols and practice in Africa. Results: In 2013, there were an estimated 33.2 million 
guideline recommendations among MAs and NHWs with uncontrolled type-2 dia-
betes. MethOds: A cross-sectional secondary data analysis was conducted using 
the continuous NHANES from 2003 to 2010. Inclusion criteria were subjects aged 20 
to < 80 years identifying themselves as MA or NHW, self-reporting as having been 
told by a provider that they have diabetes, have had diabetes for 1 or more years 
with a hemoglobin A1c of ≥ 7%. The outcome was defined as reporting the use of 
anti-diabetic medications recommended by the AACE/ACE 2009 guidelines based 
on the A1c level category (6.5%-7.5%, 7.6%-9% or > 9%). Univariate and multivariate 
logistic regression analyses were conducted to determine the likelihood of being on 
recommended treatment across race/ethnicity controlling for demographic, clinical, 
and health care access characteristics and cohort year. Results: 528 individuals 
(248 MAs and 280 NHWs) met inclusion criteria. Mean age was 48(SD= 12), 54% 
female, 82% had insurance coverage, 94% prescription drug coverage and 94% had 
a routine place for health care. Forty-seven percent of individuals were on recom-
mended treatment of which 40% were MAs and 60% were NHWs. Race/ethnicity, 
income level, insurance coverage, routine place of health care, anti-diabetic medi-
cation use and cohort year were included in the multivariate analysis. The final 
model showed routine place of care, anti-diabetic medication, and cohort year as 
statistically significant(p< 0.05). It found that, with borderline statistical significance, 
NHWs were more likely to receive recommended therapies compared to MAs(OR 
1.2,95%CI0.99-1.47,p= 0.067). cOnclusiOns: Only 47% of participants received 
recommended therapy. Routine place of care, anti-diabetic medication use and 
cohort year were significant predictors but race/ethnicity was borderline significant.
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Objectives: To assess ten year cardiovascular disease (CVD) risk in newly diag-
nosed type 2 diabetes mellitus (duration of diagnosis ≤ 6 months) patients using 
Framingham risk score(FRS) and UK Prospective Diabetes Study (UKPDS) Risk Engine 
in a public tertiary care hospital in North India and to assess the agreement between 
both the risk scores. MethOds: This is a prospective, observational, questionnaire 
based study. Patients aged 18-70 years of either sex were recruited and data were 
collected by oral interview and clinical records of patients after obtaining informed 
consent from patients. Ten year CVD risk was calculated for 324 patients using FRS 
and UKPDS Risk Engine. FRS uses participant age, sex, total cholesterol, high-density 
lipoprotein cholesterol, smoking status, blood pressure and presence or absence of 
diabetes. UKPDS Risk Engine, a diabetes specific algorithm; uses HbA1c and ethnic-
ity of the patient in addition, for assessing ten year CVD risk. Results: Out of 324 
patients [males (n) = 149; females (n) = 175], using Framingham risk score 19.1% 
are estimated with high risk, 23.1% as moderate risk, 26.2 as low risk and 31.5% as 
very low risk. The corresponding figures using UKPDS risk engine are 7.7%, 13.9%, 
10.8% and 67.6%, respectively. Inter- rater agreement assessed using weighted Kappa 
statistic showed a poor agreement between both scoring systems with a k value of 
0.18 (95% CI 0.12-0.23). cOnclusiOns: Framingham risk score overestimated the 
ten year CVD risk compared to UKPDS Risk Engine. As till date, CVD risk score devel-
opment and comparison studies were limited to European and American subjects, 
this study presents a valuable contribution regarding Indian type 2 diabetes patients.
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Objectives: To determine whether there was an association between insulin dose 
and all-cause mortality and other serious events in people with type 2 diabetes 
treated with insulin plus metformin, and to determine if concomitant metformin 
with insulin reduced the risk of adverse outcome versus insulin monother-
apy. MethOds: For this retrospective cohort study, subjects with type 2 diabetes 
who progressed to treatment with insulin monotherapy or insulin plus metformin 
from 2000 onwards were identified from the UK Clinical Practice Research Datalink 
(CPRD). The risk of all-cause mortality and a combined endpoint of any incident 
major cardiovascular event (MACE), cancer, or death were compared using the Cox 
proportional hazards model. Weight-standardised daily prescribed insulin dose 
(iu/kg/day) was modelled as a time-dependent, continuous co-variable. Results: 
13,240 subjects were identified. There were 1,840 deaths and 1,751 combined events 
(excluding those with a history of large vessel disease or cancer). The corresponding 
event rates were 43.7 deaths and 62.3 combined events per 1,000 person-years. For 
all-cause mortality, the adjusted hazard ratio (aHR) for insulin dose (relating to an 
increase of 1 iu/kg/day) was 1.81 (95% CI 1.66 to 1.98) in the combined insulin group 
(insulin ± metformin) and 1.39 (95% CI 1.10 to 1.76) in the insulin plus metformin 
group. For people in the combined insulin group (insulin ± metformin), the aHR for 
concomitant metformin was 0.48 (95% CI 0.42 to 0.54). These patterns were similar 
for the combined endpoint. cOnclusiOns: There was a dose-response association 
between insulin dose and all-cause mortality in people treated with insulin plus 
concomitant metformin. Concomitant metformin was associated with a halving of 
the risk of death in people with type 2 diabetes injecting insulin.
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to electronic health care records (EHR) data. MethOds: Using GNS Health care’s 
analytical platform (REFSTM), we built unbiased predictive models for progression 
to T2D, computationally exploring trillions of potential models, in Humedica data. 
Humedica’s data acquisition model aggregates de-identified EHR from providers 
across the continuum of care. Our study population consisted of 24,331 adults 
without history of prediabetes or T2D, from 2007-2012. Prediabetes was defined 
using World Health Organization criteria; incident T2D was identified using ICD-9 
codes. Accuracy of prediction models was assessed using an area under the curve 
(AUC) statistic. We validated resulting prediction models in an independent data-
set. Results: Our baseline model accurately predicted progression to T2D from 
normoglycemia (AUC = 0.76). We validated this model with an independent data-
set where the AUC increased to 0.78. When the model was extended to include 
time-varying covariates the AUC increased to 0.87. Our model of progression from 
normoglycemia to T2D consisted of established risk factors (blood glucose meas-
ures, hypertension, income, race, triglycerides, lipid disorders, and blood pressure), 
whereas predictors of progression to prediabetes included novel factors such as 
high-density lipoprotein, alanine aminotransferase, C-reactive protein, and core 
body temperature (AUC = 0.70). cOnclusiOns: Using an extensive EHR data-
base, we built accurate prediction models of diabetes risk using a hypothesis-free, 
machine-learning Bayesian approach, and validated them with an independent 
dataset. In doing so, we identified novel factors representing emerging areas of 
diabetes research and potential new targets for clinical management. Our ability 
to make individual T2D risk predictions has valuable applications to personalized 
medicine and clinical trial recruitment.
DiaBetes/enDocRine DisoRDeRs – cost studies
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Objectives: Estimating the budget impact of the introduction of vildagliptin as 
addition to insulin in the treatment of patients with type 2 diabetes mellitus with 
inadequate glycemic control (HbA1c> 7%) compared to the same group of patients 
treated with insulin monotherapy in Colombia, from third-party payer perspec-
tive. MethOds: Markov model, which simulates the natural history of the disease, 
budget impact analysis (AIP) was made under the Colombian context for a five-year 
period using direct health costs associated with the natural history of the disease, 
including macrovascular and microvascular events and episode of hypoglycemia 
in a mobile cohort of patients, looking at prevalence, incidence and death. In the 
alternative scenarios, it will estimate reductions in insulin doses for the correspond-
ing arm vildagliptin in addition to insulin. Direct health care costs were taken from 
insurers and individual records of health benefits (RIPS) 2012. Results: With a 
disease prevalence and incidence rate of 0.04 & 0.00879 respectively in Colombia 
and assuming that 8.6% of patients require insulin according to the stage of the dis-
ease, the cumulative cost to 5 years of patients treated with insulin alone, would be 
COP $3,030,742,552,215(USD1.565.522,80), compared to COP $3,546,840,289,383(USD 
1.832.111,85) treated with insulin + Vildagliptin. Additionally, contemplating a reduc-
tion of approximately 27% in the dose of insulin, savings were generated under the 
use of vildagliptin in addition to insulin from the third year on total cost as well as 
reduction of cardiovascular and adverse events. Similarly, savings accumulated over 
the capitation payment unit of 0.000093% in 5 years, accompanied by lower mortal-
ity. cOnclusiOns: The use of vildagliptin in addition to insulin will be significantly 
less expensive than using insulin monotherapy for patients with type 2 diabetes 
with inadequate glycemic control, in the Colombian health system context, along 
with better health care outcomes.
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Objectives: This post-hoc analysis estimated the budget impact of PHEN/TPM ER 
7.5/46 mg in comparison with lifestyle modification (LM) alone in overweight and 
obese patients with comorbid prediabetes or T2DM. MethOds: A 1-year budget 
impact model was developed from the health plan perspective evaluating pharmacy 
costs and comorbidity costs in overweight and obese patients with prediabetes or 
T2DM. Changes in body mass index (BMI) for PHEN/TPM ER 7.5/46 and LM were 
based on data from CONQUER, a phase 3, 56-week randomized trial (Gadde 2011). 
Comorbidity cost offsets for BMI reductions were calculated by multiplying the 
change in BMI by medical ($164) and pharmacy ($113) costs per unit of BMI (Wang 
2006). The rate of progression from prediabetes to T2DM was based on data from 
CONQUER. Literature-based estimates of the annual cost of treating prediabetes 
($535) and T2DM ($8069) were used to calculate comorbidity costs. The plan popula-
tion was assumed to be 1,000,000 patients and the market uptake of PHEN/TPM ER 
7.5/46 was assumed to be 1% at a weighted cost per capsule of $5.04. Results: In 
patients with prediabetes, BMI was reduced by 4.30kg/m2 for PHEN/TPM ER 7.5/46 
and 2.15kg/m2 for LM, translating to annual cost offsets of $1191 and $596, respec-
tively. The rate of progression from prediabetes to T2DM was 3.8% for PHEN/TPM ER 
and 9.6% for LM. In patients with T2DM, the BMI reduction was 3.69kg/m2 for PHEN/
TPM ER and 1.96kg/m2 for LM, translating to cost offsets of $1022 and $543, respec-
tively. The budget impact of adding PHEN/TPM ER 7.5/46 therapy was $0.01 per mem-
ber per month (PMPM) for prediabetes and $0.05 PMPM for T2DM. cOnclusiOns: 
The budget impact of adding weight management therapy with PHEN/TPM ER in 
overweight or obese patients with prediabetes or T2DM is minimal and is offset by 
reduced comorbidity costs.
adult (ages 20-79) diabetes patients in Africa, ~1.5 times the prevalence in 2003. The 
continent-wide expenditure on diabetes in 2013 was ~$7.06 billion, compared to 
$2.72 billion in 2010, accounting for ~1% of global expenditures despite a prevalence 
burden of nearly 10% of global figures. The highest proportion of diabetes cases and 
spending were from northern Africa (40.4% of cases, 41.8% expenditures in 2013). 
However, eastern Africa (23.2% cases, 7.1% expenditures), western Africa (19.3% 
cases, 10.9% expenditures), and central Africa (8.6% cases, 4.2% expenditures), shoul-
der higher burdens of disease than their share of expenditures. In contrast, southern 
Africa (8.4% cases, 36% expenditures) has a lower percentage of overall patients, but 
spends significantly more than other regions. Data indicate that access to diabetes 
treatment is highly variable by region, and that disease management programs are 
infrequently available. Drug therapies are more broadly available, though costs can 
be a significant barrier to utilization. cOnclusiOns: Rising disease prevalence will 
continue to stimulate demand for medical solutions in Africa. Northern and south-
ern Africa present a noteworthy market opportunity due to high disease prevalence 
and/or relatively high mean spending per patient. Affordable solutions that account 
for the variability in local market economics and implementation infrastructure are 
needed to support the growing diabetes burden in Africa.
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Objectives: The aim of this study was to examine the geographic, age, gender 
and racial variations in the prevalence of diabetes in the U.S. Medicaid popula-
tion. MethOds: This retrospective study analyzed a patient sample from the 
Medicaid fee-for-service (FFS) population in 2008 and 2009. Patients diagnosed with 
diabetes were identified using International Classification of Disease, 9thRevision, 
Clinical Modification (ICD-9-CM) diagnosis codes 250.x0 and 250.x2. Continuous 
Medicaid FFS enrollment was required during the 2-year study period. Patients 
were excluded if they had managed care enrollment in any month during the study 
period. Diabetes prevalence was analyzed by region, state, age, gender and race. The 
number and percentages of patients in each category were provided in the descrip-
tive analysis. Results: A total of 817,596 patients (16.66%) were diagnosed with 
diabetes among the Medicaid FFS population in 2008 through 2009. Patients over 
age 60 years had a higher prevalence (23.00%) than those age 40-59 (19.53%) or 0-39 
years (3.27%). Prevalence was also examined by race, with the highest prevalence 
found in Asian patients (22.17%), followed by Black (20.42%), Hispanic (16.89%), White 
(15.91%) and Native American (8.89%) patients. Prevalence of diabetes was much 
higher for female (18.36%) than for male patients (13.99%). U.S. states with the 
highest prevalence were Maryland (27.42%), Connecticut (26.73%), North Carolina 
(25.72%), Ohio (23.99%) and Indiana (23.51%). Prevalence trends were also strati-
fied by U.S. region: Midwest (18.12%), South (17.11%), Northeast (16.59%) and West 
(7.60%). cOnclusiOns: The study results illustrate that elderly patients had a 
higher probability of being diagnosed with diabetes. Asian patients were more likely 
to be diagnosed with diabetes compared to other races. Female patients were at a 
higher risk for diabetes. Patients who resided in the Midwest U.S. region also had 
an increased likelihood of a diabetes diagnosis.
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Objectives: Diabetes mellitus (DM) screening using hemoglobin A1c (HbA1c) is 
important to identify those at risk of cardiovascular disease. Little information is 
available on strategies for monitoring including frequency and timing of re-screen-
ing. We aimed to estimate the long-term between-person variation (“signal”) and 
short-term within-person variation (“noise”) of the HbA1c measures and evaluated 
the optical interval of re-checking HbA1c levels for DM screening. MethOds: We 
conducted a retrospective cohort study including enrolled all people who consecu-
tively visited the St. Luke’s International Hospital Centre for Preventive Medicine 
(Tokyo, Japan) for a health check-up between 2005 and 2010. We measured the serum 
HbA1c annually. We estimated the ratio of “signal” to “noise” for HbA1c, adjusting for 
age, gender, using the random effects model. When the ratio of signal to noise was 
> = 1, we considered that screening interval appropriate. Results: A total of 34,662 
apparently healthy Japanese adults not taking diabetes medication at baseline had 
annual check-ups over 5 years. The mean age of the participants was 49 years old 
(SD: 12, range: 21 to 95) and 52% were male. Mean systolic blood pressure and BMI 
were 118 mmHg (SD: 17 mmHg) and 22.7 kg/m2 (SD: 3.7), respectively. Mean HbA1c 
level was 5.6% mg/dl (SD: 0.5%). Short-term within-person variations of HbA1c was 
0.10 (coefficient of variation, 6.1%) and long-term between-person variation were 
0.06 at 5 years and 0.13 at 7 years, respectively. The ratios of signal to noise were 
0.63 at 5 years and 1.2 at 7 years, respectively. cOnclusiOns: Our findings suggest 
that the optimal interval of DM screening for healthy adults should be more than 
5 years using HbA1c.
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Objectives: Type 2 diabetes (T2D) is strongly associated with morbidity and mor-
tality, and carries a heavy financial burden. An improved understanding of the 
factors that predict progression to prediabetes and T2D is warranted. Thus our 
objective was to identify these determinants, applying ‘big data’ analytic methods 
